Press Releases
Date Title and Summary View
Sep 27, 2012 -Second-Generation Pan-Genotypic NS5A Inhibitor Achieves Potent Antiviral Activity of Mean Maximum 3.74 Log10 Reduction Following a Single Dose -- Initiated Enrollment in a Phase 2 Clinical Trial Evaluating ACH-3102 Plus Ribavirin for the Treatment of HCV Genotype 1b-- Hosting Analyst Day Today With Live Webcast Beginning at 1:00 p.m. ET - ...
Sep 21, 2012 NEW HAVEN, Conn., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it will host a live webcast of its inaugural Analyst Day on Thursday, September 27, 2012 beginning at 1:00 p.m. Eastern Time. The senior management team, led by Michael Kishbauch, President and Chief Executive Officer of Achil...
Aug 31, 2012 NEW HAVEN, Conn., Aug. 31, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present at the following investor conferences during the month of September: Citi's 7th Annual Biotech Day on Wednesday, September 5, 2012 at 10:45 a.m. ET at the Mandarin Oriental in...
Aug 30, 2012 NEW HAVEN, Conn., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has entered into a definitive agreement with funds managed by QVT Financial LP for the sale of 6,367,853 shares of its common stock. The investors have agreed to purchase the shares of common stock at a price of $6.57 per sh...
Aug 10, 2012 NEW HAVEN, Conn., Aug. 10, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that Michael Kishbauch, President and Chief Executive Officer of Achillion, will present a corporate overview at the 2012 Wedbush Pacgrow Lifesciences Management Access Conference. The presentation will take place at Le Parker Meridien ...
Aug 8, 2012 NEW HAVEN, Conn., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2012 and provided an update on the Company's portfolio of clinical stage compounds being developed for the treatment of hepatitis C virus (HCV). For the second quarter of 2...
Aug 7, 2012 Sovaprevir (formerly ACH-1625) achieves SVR4 of 85-100% of genotype 1 treatment naive patients treated with sovaprevir for 12 weeks followed by an additional 12 weeks of pegylated-interferon and ribavirinEnrollment of HCV-infected patients initiated in Phase 1 trial of ACH-3102, second generation pan-genotypic NS5A inhibitorConference call tomorrow...
Jul 31, 2012 NEW HAVEN, Conn., July 31, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to release second quarter and six-month 2012 financial results on Wednesday, August 8, 2012, before the market opens. Achillion will also host a conference call and live webcast to discuss these financial results and t...
Jul 10, 2012 NEW HAVEN, Conn., July 10, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Milind Deshpande, Ph.D., President of Research and Development, and Chief Scientific Officer of Achillion, will ...
Jun 14, 2012 NEW HAVEN, Conn., June 14, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will present a corporate overview at t...
FirstPrevious ...
7
... NextLast
Add to Briefcase = add release to Briefcase

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue